Clinical Trial Update: Targeted Next Generation Sequencing and Intellectual Disability

View source ↗

Summary

The clinical trial evaluating targeted Next Generation Sequencing in individuals with Intellectual Disability has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intellectual Disability

Snippet

Sponsor: Central Hospital, Nancy, France | Conditions: Intellectual Disability | Status: COMPLETED